Drug Topics November 1, 2024
Killian Meara

Check out these important FDA updates from the month of October 2024.

FDA Approves Abuse-Deterrent 10 mg Oxycodone Hydrochloride for Severe Pain

The FDA approved oxycodone hydrochloride (Roxybond) immediate-release (IR) CII 10 mg tablets for the management of severe pain that requires opioid analgesic treatment and for which alternative treatments are inadequate.

FDA Approves Sulopenem Etzadroxil and Probenecid for Uncomplicated UTIs

The FDA approved Iterum Therapeutics’ sulopenem etzadroxil and probenecid (Orlynvah) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneuomoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options.

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies
Related Articles:
FDA updates definition of 'healthy'
FDA Clears Withings’ New Blood Pressure Monitor That Allows Providers to Communicate Directly with Patients
4 takeaways from the FDA’s first digital health advisory committee
FDA commissioner, a veteran cardiologist, highlights ongoing issues with US healthcare system
FDA commissioner urges health systems to strengthen AI quality oversight

Share This Article